Last updated: Jun 9, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07005102 | 2, 3 | A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | c-Met -- antibody-drug conjugate (telisotuzumab adizutecan) plus EGFR TKI (osimertinib) |
| NCT06694454 | 1, 2 | Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) | DNA methyltransferases -- epigenetic inhibitor (azacytidine) + PD-L1 -- immune checkpoint inhibitor (durvalumab) + platinum-based chemotherapy |
| NCT06170788 | 3 | Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) | Trop-2 -- antibody-drug conjugate (ADC) (Sacituzumab tirumotecan); PD-1 -- immune checkpoint inhibitor (Pembrolizumab) |
| NCT04613596 | 2, 3 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | KRAS G12C + PD-1 -- KRAS G12C covalent inhibitor + PD-1 inhibitor |
| NCT07322341 | 2 | SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer | CXCR1/2 + PD-L1 -- CXCR1/2 inhibitor + PD-L1 inhibitor |
| Sponsor | Recruiting trials |
|---|---|
| Sun Yat-sen University | 34 |
| Shanghai Pulmonary Hospital, Shanghai, China | 30 |
| Tianjin Medical University Cancer Institute and Hospital | 27 |
| Hunan Province Tumor Hospital | 23 |
| AstraZeneca | 22 |
Countries/regions with the most active trial sites for lung cancer (nsclc). A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 1, 2026 | NCT06638125 | 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial | Indocyanine green -- fluorescent dye for surgical navigation |
| Nov 30, 2026 | NCT07579221 | Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer | EZH2 + PRMT5 -- epigenetic enzyme inhibitors |
| Sep 14, 2026 | NCT07619599 | A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab | PD-1 -- antibody (immune checkpoint inhibitor) |
| Aug 7, 2026 | NCT07012031 | Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation | KRAS G12C -- covalent inhibitor + HER2 -- antibody-drug conjugate (ADC) |
| Aug 1, 2026 | NCT07436858 | Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer | HER2 -- radiolabeled antibody for PET imaging (diagnostic antibody) |
| Jul 31, 2026 | NCT07617337 | AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer | ALK -- tyrosine kinase inhibitor (TKI) |
| Jul 1, 2026 | NCT07495098 | Phase 1B Trial of Intratumoral Cisplatin for Stage IV Lung Cancer | DNA crosslinking agent -- platinum-based chemotherapy (small molecule) |
| Jul 1, 2026 | NCT07382726 | Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial | KRAS G12C -- covalent inhibitor (Adagrasib); B7-H3 -- antibody-drug conjugate (ADC) (Izalontamab Brengitecan) |
You've seen the lung cancer (nsclc) landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.